Navigation Links
Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Date:11/29/2007

Management and Third-Party Investigators to Conduct Conference Call on December 10, 2007 to Discuss SNS-595 Clinical Trial Results and SNS-032

Non-clinical Data

SOUTH SAN FRANCISCO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that it will present data on the company's two lead product candidates, SNS-595 and SNS-032, at the upcoming 49th Annual Meeting of the American Society of Hematology (ASH). This year's conference will be held December 8-11, 2007 at the Georgia World Congress Center in Atlanta, Georgia. On December 10, 2007, Sunesis management will host a conference call for investors to discuss the data being presented.

Jeffrey Lancet, M.D., of the H. Lee Moffitt Cancer Center & Research Institute will present results from Sunesis' Phase 1 clinical trial of SNS-595, a replication-dependent DNA damaging agent, as part of the oral session "Acute Myeloid Leukemias: Therapy, excluding Transplantation-Novel Therapies." The presentation, titled "SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia," (Abstract no. 442), will be conducted in Room A411-A412 at 2:15 p.m. Eastern Time on Monday, December 10, 2007.

In addition, the company will present non-clinical data on SNS-032, a cyclin-dependent kinase (CDK) inhibitor, during poster session "CLL: Salvage Therapies and New Agents." The poster, "Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol" (Abstract no. 3112) will be presented in Hall B4 of the Georgia World Congress Center on Monday December 10, 2007 from 10:30 a.m. to 7:00 p.m.

Conference Call Information

Sunesis management will host a conference call to discuss data being presented at the ASH meeting on Monday, December 10, 2007 at 4:00 p.m. Eastern Time/1:00 p.m. Pacific Time. Joining management on the call will be clinical investigators involved in the clinical trial of SNS-595and the non-clinical studies of SNS-032.

Individual and institutional investors can access the call via 877-723-9519 (U.S. and Canada) or 719-325-4841 (international). To access the live audio webcast, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. SNS-595, a replication-dependent DNA damaging agent, is currently in Phase 1 and Phase 1b clinical trials of patients with acute leukemia and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ACME Markets, Delaware County ... Councilman Dave White announced today the availability ... pharmacies across Delaware County . According ... has saved 26,463 lives nationwide over the past 20 years. Since ... were authorized to administer naloxone to overdose victims, 244 lives ...
(Date:5/3/2016)... May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating ... video of two patients who tell their personal story and encourage those at risk to ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... 2016 Intec Pharma Ltd. (NASDAQ: ... company, today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in ... outstanding track record, having supported the advancement of several ... in the United States and ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... operators of commercial real estate proudly announced that its service-based charitable program, Olshan ... Team members portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with ...
(Date:5/4/2016)... ... 04, 2016 , ... A new collaboration will give more researchers access to ... (DCRI) and analytics leader SAS will provide researchers worldwide with data management and analytics ... Health System. , The DCRI and SAS share the goal of greater transparency ...
(Date:5/4/2016)... ... ... May kicked off with Melanoma Monday , a multi-agency effort to raise ... encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, and Plano, ... in the future. , The dermatology-specific awareness month ends with “Don’t Fry Day,” established ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... of foundational nutrients that supports cellular and metabolic health. This synergistic combination of ... mg free-form curcumin, along with 150 mg of reduced glutathione and 200 mg ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... and the pharmacy industry, today announced that it was chosen as the Pharmaceutical ... (APPA) Industry Awards . The awards acknowledge the hard work and dedication of ...
Breaking Medicine News(10 mins):